Neurocrine Biosciences, Inc’s filing revealed that its Director GORMAN KEVIN CHARLES unloaded Company’s shares for reported $13.44 million on Aug 07 ’25. In the deal valued at $126.41 per share,106,322 shares were sold. As a result of this transaction, GORMAN KEVIN CHARLES now holds 514,596 shares worth roughly $63.8 million.
Then, KEVIN CHARLES GORMAN bought 106,322 shares, generating $13,654,934 in total proceeds.
Before that, Delaet Ingrid sold 457 shares. Neurocrine Biosciences, Inc shares valued at $61,695 were divested by the Chief Regulatory Officer at a price of $135.00 per share. As a result of the transaction, Delaet Ingrid now holds 4,730 shares, worth roughly $0.59 million.
Truist initiated its Neurocrine Biosciences, Inc [NBIX] rating to a Buy in a research note published on July 21, 2025; the price target was $163. A number of analysts have revised their coverage, including Goldman’s analysts, who began to cover the stock in early July with a ‘”a Buy”‘ rating. Needham also remained covering NBIX and has increased its forecast on April 15, 2025 with a “Buy” recommendation from previously “Hold” rating. RBC Capital Mkts revised its rating on April 14, 2025. It rated NBIX as “an Outperform” which previously was an “a Sector perform”.
Price Performance Review of NBIX
On Monday, Neurocrine Biosciences, Inc [NASDAQ:NBIX] saw its stock fall -0.82% to $123.98. Over the last five days, the stock has lost -3.17%. Neurocrine Biosciences, Inc shares have fallen nearly -13.98% since the year began. Nevertheless, the stocks have fallen -9.17% over the past one year. While a 52-week high of $154.87 was reached on 01/30/25, a 52-week low of $84.23 was recorded on 04/09/25.
Levels Of Support And Resistance For NBIX Stock
The 24-hour chart illustrates a support level at 123.14, which if violated will result in even more drops to 122.31. On the upside, there is a resistance level at 125.36. A further resistance level may holdings at 126.75.
How much short interest is there in Neurocrine Biosciences, Inc?
A steep rise in short interest was recorded in Neurocrine Biosciences, Inc stocks on 2025-07-15, dropping by -0.26 million shares to a total of 3.23 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 3.5 million shares. There was a decline of -8.07%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on February 11, 2025 when Deutsche Bank began covering the stock and recommended ‘”a Hold”‘ rating along with a $138 price target.
